Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy.
Haemorrhagic myocarditis is a rare but important complication of cyclophosphamide therapy. Echocardiographic identification of the disorder can be made. We believe that the ultrasound features of this disorder have not been previously reported.
Department of Oncologic Imaging, Cross Cancer Institute, Edmonton, Alberta, Canada.
I W
IW
Birchall
Z
Z
Lalani
P
P
Venner
J
J
Hugh
D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects*; D004452:Echocardiography / Q000379:methods; D017809:Fatal Outcome; D006406:Hematoma / Q000139:chemically induced; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D009205:Myocarditis / Q000139:chemically induced*; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy / Q000556:secondary; D012187:Retroperitoneal Space; D013736:Testicular Neoplasms / Q000188:drug therapy
D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide